Factory 99% Vinorelbine Tartrate Powder CAS 125317-39-7 Chemical Intermediate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A878
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Vinorelbine Tartrate
• CAS: 125317-39-7
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Vinorelbine Tartrate
Appearance	White Powder
CAS NO.	125317-39-7
Storage	Keep in a cool, dry, dark location

 

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid derived from the periwinkle plant (Catharanthus roseus). It is a chemotherapeutic agent used in the treatment of various types of cancer. Vinorelbine Tartrate exists as a white to off-white powder that is soluble in water and is commonly formulated as an injectable solution or oral capsule for clinical use.

 

1. Cancer Treatment: Vinorelbine Tartrate is primarily used in the treatment of solid tumors, including non-small cell lung cancer, metastatic breast cancer, ovarian cancer, and lymphoma. It is often administered in combination with other chemotherapeutic agents to enhance efficacy.

2. Intravenous and Oral Administration: Depending on the specific formulation, Vinorelbine Tartrate can be administered either intravenously or orally. The intravenous formulation is typically given once weekly, while the oral capsule is taken once weekly, usually during a meal.

3. Dosage Adjustments: The dosage of Vinorelbine Tartrate is tailored to the individual patient based on factors such as body surface area, renal and hepatic function, and tolerance to the drug. Dose reductions or discontinuation may be necessary in cases of severe toxicity.

1. Inhibition of Microtubule Assembly: Vinorelbine Tartrate exerts its anticancer effects by interfering with the assembly of microtubules, which are essential components of the cell's cytoskeleton. By disrupting microtubule function, Vinorelbine Tartrate blocks cell division, leading to cell death.

2. Cell Cycle Arrest: The drug specifically targets cells in the G2 and M phases of the cell cycle, preventing them from progressing to the next phase. This arrest disrupts the normal proliferation of cancer cells.

3. Antitumor Activity: Vinorelbine Tartrate has demonstrated significant antitumor activity in preclinical and clinical studies. It has been shown to prolong survival and improve quality of life in patients with advanced cancer, particularly when used in combination with other chemotherapeutic agents.